ArticleRevista medica del Instituto Mexicano del Seguro Social2025
[Hidradenitis suppurativa, report with dual therapy: small molecules and biological therapy].
Article in Revista medica del Instituto Mexicano del Seguro Social, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- American Academy of Dermatology 2026 Annual Meeting: Updates in Hidradenitis Suppurativa Medical Management.Dermatology and therapy · 2026Review
- Dual immunomodulator therapy with upadacitinib and bimekizumab in severe hidradenitis suppurativa: A case report.JAAD case reports · 2026Article
- Dual Targeted Therapy for Hidradenitis Suppurativa: A Narrative Review.Dermatology and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hidradenitis suppurativa is an immune-mediated disease characterized by abscesses, deep nodules and fistulas that connect them to each other or connect to the surface, creating infectious processes that are difficult to control, healing of fistulas, retractable tracts and painful ulcers of slow evolution that lead the patient to depression and anxiety. Treatment still shows unsatisfactory results for patient health. Clinic case: A 27-year-old woman with a 5-year history of this pathology in Hurley stage III is presented. Because of failure to treatment with first lines of management. Anti IL-17 biologic was started, with poor response, so JAK inhibitor was added with adequate response at 4 weeks in the modified Hurley scale, VAS of pain and DLQI. Conclusion: Combined therapy mediated by cytokines and cells of the humoral response of retractile and fistulous lesions in Hurley stages II and III is proposed as an adjuvant in the chronic response of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.